Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure

AIMS: The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease. We report herein the pre‐specified subgroup analysis in patients w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Heart Fail
Autori principali: Rossignol, Patrick, Williams, Bryan, Mayo, Martha R., Warren, Suzette, Arthur, Susan, Ackourey, Gail, White, William B., Agarwal, Rajiv
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Ltd. 2020
Soggetti:
TREATMENT
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540031/
https://ncbi.nlm.nih.gov/pubmed/32452085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1860
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi